Hosted on MSN
FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 kilograms with ...
Seeking Alpha
Johnson & Johnson gets FDA nod for pediatric use of Tremfya
Johnson & Johnson (NYSE:JNJ) announced that the U.S. FDA has granted approval for Tremfya (guselkumab) to treat children aged six and older, weighing at least 40 kg, and suffer from moderate to severe ...